Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
• Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients
• Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work
• Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
|
|
|
|
|
11-50 employees
View all Sunesis Pharmaceuticals employees
|
|
|
Biotechnology
|
|
|
$10M–$50M
|
|
|
(415) 625-0000
|
|
|
395 Oyster Point Blvd., Ste. 400, South San Francisco, CA 94080, US
|
|
|
1987
|
The decision makers in Sunesis Pharmaceuticals, Inc. are Cindy Lopez, Craig Rodenberger, Joanna Deredita, etc. Click to Find Sunesis Pharmaceuticals, Inc. decision makers emails.
Sunesis Pharmaceuticals headquarters is located at 395 Oyster Point Blvd., Ste. 400, South San Francisco, CA 94080, US.
Sunesis Pharmaceuticals generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact Sunesis Pharmaceuticals by calling (415) 625-0000.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.